Malaria Is Associated With Kaposi Sarcoma-Associated Herpesvirus Seroconversion in a Cohort of Western Kenyan Children.
HHV-8
KSHV
Kaposi sarcoma-associated herpesvirus
malaria
sub-Saharan Africa
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
12
08
2020
accepted:
25
11
2020
pubmed:
30
11
2020
medline:
2
2
2022
entrez:
29
11
2020
Statut:
ppublish
Résumé
We aimed to determine whether Plasmodium falciparum infection affects age of Kaposi sarcoma-associated herpesvirus (KSHV) seroconversion in Kenyan children. Kenyan children (n = 144) enrolled at age 1 month, from 2 sites with different levels of malaria transmission (stable/high vs unstable/low) were followed to age 24 months. Plasma was tested for KSHV antibodies using enzyme-linked immunosorbent assay (ELISA; K8.1 and LANA) and a multiplex bead-based assay (K8.1, K10.5, ORF38, ORF50, and LANA) and whole blood tested for P. falciparum DNA using quantitative PCR. Cox proportional hazards models were used to assess associations between P. falciparum DNA detection, malaria annualized rate (P. falciparum detections/person-years), and enrollment site (malaria-high vs malaria-low) with time to KSHV seroconversion. KSHV seroprevalence was 63% by age 2 years when assessed by multiplex assay. Children with P. falciparum were at increased hazards of earlier KSHV seroconversion and, among children with malaria, the hazard of becoming KSHV seropositive increased significantly with increasing malaria annualized rate. Children from the malaria-high transmission region had no significant difference in hazards of KSHV seroconversion at 12 months but were more likely to become KSHV seropositive by age 24 months. Malaria exposure increases the risk for KSHV seroconversion early in life.
Sections du résumé
BACKGROUND
We aimed to determine whether Plasmodium falciparum infection affects age of Kaposi sarcoma-associated herpesvirus (KSHV) seroconversion in Kenyan children.
METHODS
Kenyan children (n = 144) enrolled at age 1 month, from 2 sites with different levels of malaria transmission (stable/high vs unstable/low) were followed to age 24 months. Plasma was tested for KSHV antibodies using enzyme-linked immunosorbent assay (ELISA; K8.1 and LANA) and a multiplex bead-based assay (K8.1, K10.5, ORF38, ORF50, and LANA) and whole blood tested for P. falciparum DNA using quantitative PCR. Cox proportional hazards models were used to assess associations between P. falciparum DNA detection, malaria annualized rate (P. falciparum detections/person-years), and enrollment site (malaria-high vs malaria-low) with time to KSHV seroconversion.
RESULTS
KSHV seroprevalence was 63% by age 2 years when assessed by multiplex assay. Children with P. falciparum were at increased hazards of earlier KSHV seroconversion and, among children with malaria, the hazard of becoming KSHV seropositive increased significantly with increasing malaria annualized rate. Children from the malaria-high transmission region had no significant difference in hazards of KSHV seroconversion at 12 months but were more likely to become KSHV seropositive by age 24 months.
DISCUSSION
Malaria exposure increases the risk for KSHV seroconversion early in life.
Identifiants
pubmed: 33249494
pii: 6010567
doi: 10.1093/infdis/jiaa740
pmc: PMC8280487
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
303-311Subventions
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239588
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA102667
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Infect Dis. 2004 Oct 15;190(8):1382-6
pubmed: 15378429
Lancet. 2005 Mar 26-Apr 1;365(9465):1147-52
pubmed: 15794969
Br J Cancer. 2001 Aug 3;85(3):379-82
pubmed: 11487269
Parasitol Res. 2016 Jun;115(6):2131-7
pubmed: 27053131
PLoS One. 2013 May 29;8(5):e64636
pubmed: 23734210
Science. 2014 Aug 1;345(6196):573-7
pubmed: 24968940
BMC Infect Dis. 2010 May 12;10:115
pubmed: 20462453
J Med Virol. 2001 Jun;64(2):157-66
pubmed: 11360248
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e41-3
pubmed: 24872135
J Immunol Methods. 2010 Apr 30;356(1-2):39-46
pubmed: 20211626
Infect Agent Cancer. 2011 Sep 30;6(1):15
pubmed: 21962023
Infection. 2003 Jan;31(1):47-50
pubmed: 12590333
PLoS Negl Trop Dis. 2019 Oct 16;13(10):e0007776
pubmed: 31618208
PLoS One. 2014 Aug 25;9(8):e105017
pubmed: 25153531
Sci Rep. 2016 Nov 14;6:36958
pubmed: 27841361
Front Microbiol. 2016 Feb 15;7:151
pubmed: 26913028
J Infect Dis. 2012 Mar 15;205(6):906-13
pubmed: 22301635
PLoS Pathog. 2014 Mar 27;10(3):e1004046
pubmed: 24675986
Infect Agent Cancer. 2020 Nov 26;15(1):71
pubmed: 33292357
Pediatr Infect Dis J. 2018 Aug;37(8):e225-e228
pubmed: 29369149
Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):300-8
pubmed: 24296855
J Infect Dis. 2018 Jan 4;217(2):263-269
pubmed: 29099933
Med Vet Entomol. 2003 Dec;17(4):461-4
pubmed: 14651663
J Infect Dis. 2018 Aug 24;218(7):1061-1065
pubmed: 29741631
Front Microbiol. 2016 Aug 12;7:1149
pubmed: 27570517
Malar J. 2019 Jan 22;18(1):19
pubmed: 30670032
Clin Infect Dis. 2020 Aug 14;71(4):1055-1062
pubmed: 31555829
Nature. 1996 Oct 31;383(6603):787-93
pubmed: 8893001
Cancer Epidemiol. 2014 Apr;38(2):137-43
pubmed: 24631417
J Infect Dis. 2020 Jun 16;222(1):111-120
pubmed: 32072172
J Med Virol. 2016 Nov;88(11):1973-81
pubmed: 27062052
Pediatr Infect Dis J. 1999 Sep;18(9):795-9
pubmed: 10493340
J Infect Dis. 2011 Mar 1;203(5):625-34
pubmed: 21273188
Trop Med Int Health. 2015 May;20(5):665-672
pubmed: 25611008
Int J Cancer. 2015 Jun 15;136(12):2822-30
pubmed: 25395177
Parasite Immunol. 2006 Jan-Feb;28(1-2):35-49
pubmed: 16438675
J Infect Dis. 2016 Nov 1;214(9):1390-1398
pubmed: 27571902
J Infect Dis. 2009 Aug 1;200(3):430-8
pubmed: 19534596
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):228-33
pubmed: 23403859
Int J Mol Med. 2001 May;7(5):535-8
pubmed: 11295117
IARC Monogr Eval Carcinog Risks Hum. 2014;104:9-350
pubmed: 26173303